Disfunzioni sessuali correlate al trattamento del disturbo depressivo maggiore con farmaci antidepressivi

Titolo Rivista RIVISTA DI SESSUOLOGIA CLINICA
Autori/Curatori Luigi Lombardo, Roberta Rossi
Anno di pubblicazione 2014 Fascicolo 2014/2
Lingua Italiano Numero pagine 24 P. 57-80 Dimensione file 123 KB
DOI 10.3280/RSC2014-002003
Il DOI è il codice a barre della proprietà intellettuale: per saperne di più clicca qui

Qui sotto puoi vedere in anteprima la prima pagina di questo articolo.

Se questo articolo ti interessa, lo puoi acquistare (e scaricare in formato pdf) seguendo le facili indicazioni per acquistare il download credit. Acquista Download Credits per scaricare questo Articolo in formato PDF

Anteprima articolo

FrancoAngeli è membro della Publishers International Linking Association, Inc (PILA)associazione indipendente e non profit per facilitare (attraverso i servizi tecnologici implementati da CrossRef.org) l’accesso degli studiosi ai contenuti digitali nelle pubblicazioni professionali e scientifiche

Il Disturbo Depressivo Maggiore è uno dei disturbi psichiatrici più diffusi. Studi epidemiologici e clinici mostrano che la depressione e la sua cura sono associate, sia negli uomini che nelle donne, a disfunzioni sessuali quali difficoltà dell’orgasmo e dell’eccitazione, desiderio sessuale ipoattivo, eiaculazione precoce e difficoltà erettili. Le disfunzioni sessuali correlate all’uso di farmaci antidepressivi sono da considerare importanti effetti collaterali spesso sottovalutati e sono frequentemente indicati come causa di scarsa adesione alla cura, discontinuità nel trattamento o abbandono della terapia. Gli antidepressivi con una forte attività serotoninergica (SSRI e SNRI) hanno i tassi più alti di effetti collaterali sulla sessualità. Lo scopo di questa revisione della letteratura è quello di descrivere gli aspetti epidemiologici e clinici delle disfunzioni sessuali correlate alle principali categorie di farmaci antidepressivi e le strategie per gestire questo problema, inclusi gli approcci farmacologici e quelli alternativi.;

Keywords:Depressione, disfunzione sessuale, farmaci antidepressivi, disturbi sessuali, effetti collaterali sessuali, farmaco-indotto, disfunzioni sessuali correlate alla terapia.

  1. Abdel-Hamid I.A. (2006). Pharmacologic treatment of rapid ejaculation: levels of evidence-based review. Current Clinical Pharmacology, 1(3): 243-54. DOI: 10.2174/15748840677824935
  2. Álvarez E., Viñas F. (2010). Mirtazapine in combination. Actas Españolas de Psiquiatría, 38(2): 121-8.
  3. Amini K., Negarandeh R., Cheraghi M.A., Eftekhar M. (2013). Major depressive disorder: a qualitative study on the experiences of Iranian patients. Issues in Mental Health Nursing, 34(9):685-92. DOI: 10.3109/01612840.2013.789942
  4. Atlantis E., SullivanT. (2012). Bidirectional association between depression and sexual dysfunction: a sistematic review and meta-analysis. The Journal of Sexual Medicine, 9(6): 1497-507. DOI: 10.1111/j.1743-6109.2012.02709.x
  5. Balwin D.S. (2001). Depression and sexual dysfunction. British Medical Bulletin, 57: 81-99.
  6. Baldwin D., Bridgman K., Buis C. (2006). Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. Journal of Psychopharmacology, 20(1): 91-6.
  7. Balon R., Segraves R.T., Clayton A. (2007). Issues for DSM-V: sexual dysfunction, disorder, or variation along normal distribution: toward rethinking DSM criteria of sexual dysfunctions. The American Journal of Psychiatry, 164: 198-200.
  8. Balon R. (2008). The DSM criteria of sexual dysfunction: need for a change. Journal of Sex and Marital Therapy, 34: 186-197. DOI: 10.1080/00926230701866067
  9. Behnke K., Sogaard J., Martin S., Baüml J., Ravindran A.V., Agren H., Vester-Blokland E.D. (2003). Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. Journal of Clinical Psychopharmacology, 23: 358-364.
  10. Bijlsma E.Y., Chan J.S.W., Olivier B., Veening J.G., Millan M.J., Waldinger M.D., Oosting R.S. (2013). Sexual side effects of serotonergic antidepressants: Mediated by inibition of serotonin on central dopamine release? Pharmacology, Biochemistry and Behavior. DOI: 10.1016/j.pbb.2013.10.004
  11. Bly M.J., Bishop J.R., Thomas K.L., Ellingrod V.L. (2013). P-glycoprotein (PG polimorphism and sexual dysfunction in female patients with depression and SSRI-associated sexual side effects. Journal of Sex and Marital Therapy, 39(3):280-8. DOI: 10.1080/0092623X.2011.615896
  12. Boyarsky B.K., Hirschfeld R.M. (2000). The managment of medication-induced sexual dysfunction. Essential Psychopharmacology, 3:39-58.
  13. Clayton A.H., Pradko J.F., Croft H.A., Montano C.B., Leadbetter R.A., Bolden-Watson C., Bass K.L., Donahue R.M., Jamerson B.D., Mets A. (2002). Prevalence of sexual dysfunction among newer antidepressants. The Journal of clinical psychiatry, 63(4): 357-66.
  14. Clayton A.H., Montejo A.L. (2006). Major depressive disorder, antidepressants, and sexual dysfunction. The Journal of Clinical Psychiatry, 6:33-7.
  15. Clayton A., Keller A., McGrvey E. (2006). Burden of phase-specific sexual dysfunction with SSRIs. Journal of affective disorders, 91: 27-32.
  16. Clayton A.H., Croft H.A., Handiwala L. (2014). Antidepressants and sexual dysfunction: mechanisms and clinical implications. Postgraduate Medicine, 126(2): 91-9. DOI: 10.3810/pgm.2014.032744
  17. Corretti G., Pierucci S., De Scisciolo M., Nisita C. (2006). Comorbidity between social phobia and premature ejaculation: study on 242 males affected by sexual disordres. Journal of Sex and Marital Therapy, 32: 183-187.
  18. Dèttore D. (2001). Psicologia e psicopatologia del comportamento sessuale. Milano: McGraw-Hill.
  19. Dobkin R.D., Menza M., Marin H., Allen L.A., Rousso R., Leiblum S.R. (2006). Bupropion improves sexual functioning in depressed minority women: an open-label switch study. Journal of Clinical Psychopharmacology, 26: 21-26.
  20. Dording C.M., Mischoulon D., Shyu I., Alpert J.E., Papakostas G.I. (2012). Same and sexual functioning. European psychiatry: the journal of the Association of European Psychiatrists, 27(6): 451-4. DOI: 10.1016/j.eurpsy.2011.01.003
  21. Fagiolini A., Comandini A., Catena Dell'Osso M., Kasper S. (2012). Rediscovering trazodone for the treatment of major depressive disorder. CNS drugs, 26(12): 1033-49. DOI: 10.1007/s40263-012-0010-5
  22. Fabre L.F., Smith L.C. (2012). The effect of major depression on sexual function in women. The Journal of Sexual Medicine, 9(1): 231-9. DOI: 10.1111/j.1743-6109.2011.02445.x
  23. Sapetti A. (2012). Agomelatine: an antidepressant without deterioration of sexual response. Journal of Sex and Marital Therapy, 38(2): 190-7. DOI: 10.1080/0092623X2011.613095
  24. Fooladi E., Bell R.J., Davis S.R. (2012). Managment strategies in SSRI-associated sexual dysfunction in women at midlife. Climacteric: the Journal of the International Menopause Society, 15(4): 306-16. DOI: 10.3109/13697137.2012.658461
  25. Galecki P., Florkowski A. (2010). Effectiveness of trazodone in the treatment of sexual dysfunctions. Polski merkuriusz lekarski: organ Polskiego Towarzystwa Lekarskiego, 29(169): 66-9.
  26. Galecki P., Depko A., Wo􀄨niak A., Talarowska M. (2011). Depressive disorde, treatment and sexual dysfunction part II. Polski merkuriusz lekarski: organ Polskiego Towarzystwa Lekarskiego, 31(184): 256-9.
  27. Gartlehener G., Hansen R.A., Morgan L.C., Thaler K., Lux L.J., Van Noord M., Mager U., Gaynes B.N., Thieda P., Strobelberger M., Lloyd S., Reichenpfader U., Lohr K.N. (2011). Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: An Update of the 2007 Comparative Effectiveness Review [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US), Report No: 12-EHC012-EF. AHRQ Comparative Effectiveness Reviews.
  28. Giuliano F., Hellstrom W.J. (2008). The pharmacological treatment of premature ejaculation. BJU international, 102(6): 668-75. DOI: 10.1111/j.1464-410X2008.07719.x
  29. Gocmez S.S., Utkan T., Gacar N. (2013). Chronic administration of imipramine but not agomelatine and moclobemide affects the nitrergic relaxation of rabbit corpus cavernosum smooth muscle. European Journal of Pharmacology, 714(1-3): 442-7. DOI: 10.1016/j.ejphar.2013.07.003
  30. Graf H., Walter M., Metzger C.D., Abler B. (2013). Antidepressant-related sexual dysfunction – Perspectives from neuroimaging. Pharmacology, Biochemistry and Behavior. DOI.org./10.1016/j.pbb.2013.12.003.
  31. Gregorian R.S., Golden K.A., Bahce A., Goodman C., Kwong W.J., Khan Z.M. (2002). Antidepressant-induced sexual dysfunction. The Annals of Pharmacotherapy, 36: 1557-1589.
  32. Grover S., Shah R., Dutt A., Avasthi A. (2012). Prevalence and pattern of sexual dysfunction in married females receiving antidepressants: an exploratory study. Journal of Pharmacology and Pharmacotherapeutics, 3(3): 259-65. DOI: 10.4103/0976-500X.99430
  33. Harrison W.M., Rabkin J.G., Ehrhardt A.A., Stewart J.W., McGrath P.J., Ross D., Quitkin F.M. (1986). Effects of antidepressant medication on sexual function: a controlled study. Journal of Clinical Psychopharmacology, 6: 144-149.
  34. Hartmann U.H., Rüffer-Hesse C., Krüger T.H., Philippsohn. (2012). Individual and dyadic barriers to a pharmacotherapeutic treatment of hipoactive sexual desire disorders: resuts and implications from a small-scale study with bupropion. Journal of Sex and Marital Therapy, 38(4): 325-48. DOI: 10.1080/0092623X2011.606495
  35. Hellstrom W.J. (2010). Available and future Thérapies for premature ejaculation. Drugs of today, 46(7): 507-21. DOI: 10.13558/dot.2010.46.7.1508036
  36. Hellstrom W.J. (2011). Update on treatments for premature ejaculation. International Journal of Clinical Practice, 65(1): 16-26. DOI: 10.1111/j.1742-1241.2010.02479.x
  37. Hu X., Bull S., Hunkeler E., Ming E., Lee J., Fireman B., Markson L.E. (2004).
  38. Incidence and duration of side effects and those rated as bothersome with selective serotonine reuptake inibitor treatment for depression. The Journal of Clinical Psychiatry, 65: 959-965.
  39. Ishak W.W., Christiansen S., Sayer G., Ha K., Li N., Miller J., Nguyen J.M., Cohen R.M. (2013). Sexual satisfaction and quality of life in major depressive disorder before and after treatment with citalopram in the STAR'D study. The Journal of Clinical Psychiatry, 74(3): 256-61. DOI: 10.4088/JCP.12m07933
  40. Jarema M., Dudek D., Landowski J., Heitzman J., Rabe-Jablo􀄔ska J., Rybakowski J. (2011). Trazodon-the antidepressant: machanism of action and its position in the treatment of depression. Psychiatria Polska, 45(4): 611-25. Kamba B., Aucoin M., Lytle M., Vermani M., Maldonado A., Iorio C., Cameron C., Tsirgielis D., D’Ambrosio C., Anand L. (2013). Efficacy of acupuncture treatment of sexual dysfunction secondary to antidepressants. Journal of Alternative and Complementary Medicine, 19(11): 862-9. DOI: 10.1089/acm
  41. 2012.0751.
  42. Kaplan H.I., Sadock B.J. (1996). Pocket Handbook of Psychiatric Drug Treatment. Baltimore: Williams & Wilkins (trad. It.: Farmaci in Psichiatria. Pocket Handbook. Torino: Centro Scientifico Internazionale srl, 1997).
  43. Kashani L., Raisi F., Saroukhani S., Sohrabi H., Modabbemia A., Nasehi A.A., Jamshidi A., Ashrafi M., Mansouri P., Ghaelli P., Akhondzadeh S. (2013). Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study. Human Psychopharmacology, 28(1): 54-60. DOI: 10.1002/hup.2282
  44. Kennedy S.H., Eisfeld B.S., Dickens S.E., Bacchiochi J.R., Bagby R.M. (2000). Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. The Journal of Clinical Psychiatry. 61: 276-28.
  45. Kessler R.C., Berglund P., Demler O., Jin R., Koretz D., Merikangas K.R., Rush A.J., Walters E.E., Wang P.S. (2003). The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA, 289:3095-3105.
  46. Kikuchi T., Suzuki T., Uchida H., Watanabe K., Kashima H. (2011). Subjective recognition of adverse events with antidepressant in people with depression: a prospective study. Journal of Affective Disorders, 135(1-3): 347-53. DOI: 10.1016/j.jad.2011.07.011
  47. Kinzl J.F. (2009). Major depressive disorder, antidepressants and sexual dysfunction. Neuropsychiatrie: Klinik, Diagnostik, Thérapie und Rehabilitation: Organ der Gesellschaft Österreichischer Nervenärzte und Psychiater, 23(2): 134-8.
  48. Koshino Y., Bahk W.M., Sakai H., Kobayashi T. (2013). The efficacy and safety bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients. Neuropsychiatrie: Klinik, Diagnostik, Thérapie und Rehabilitation: Organ der Gesellschaft Österreichischer Nervenärzte und Psychiater Dis Treat, 9:1273-80. DOI: 10.2147/NDT.S48158
  49. Kurose K., Hiratsuka K., Ishiwata K., Nishikawa J., Nonen S., Azuma J., Kato M., Wakeno M., Okugawa G., Kinoshita T., Kurosawa T., Hasegawa R., Saito Y. (2012). Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression. Psychiatry Research, 15, 198(3): 424-9. DOI: 10.1016/j.psycres.2012.01.023
  50. La Torre A., Giupponi G., Duffy D., Conca A. (2013). Sexual Dysfunction Related to Psychotropic Drugs: a critical review–Part I: Antidepressants. Pharmacopsychiatry, 46:191-199. DOI: 10.1055/s-0033-1358683
  51. Labbate L.A. (2008). Psychotropics and sexual dysfunction: the evidence and the treatments. Advances in Psychosomatic Medicine, 29: 107-130. DOI: 10.1159/000126627.
  52. Langworth S., Bodlund o., Agren H. (2006). Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder. Journal of Clinical Psychopharmacology, 26(2): 121-7.
  53. Lee T.I., Issac J., Lin S.H., Yeh T.L., Lee I.H., Chen P.S., Chen K.C., Yang Y.K. (2013) Gender difference in antidepressant-related sexual dysfunction in Taiwan. General Hospital Psychiatry, 35(4): 407-11. DOI: 10.1016/j.Genhhosppsych.2013.03.015
  54. Leucht C., Huhn M., Leucht S. (2012). Amitriptyline versus placebo for major depressive disorder. The Cochrane database of systematic reviews, 12: CD009138. DOI: 10.1002/14651858.CD009138.pub2
  55. Liang C.S., Ho P.S., Chiang K.T., Su H.C. (2012). 5-HT2A receptor-1438 G/A polymorphism and serotoninergic antidepressant-induced sexual dysfunction in male patients with major depressive disorder: a prospective exploratory study. The Journal of Sexual Medicine, 9(8): 2009-16. DOI: 10.1111/j.1743
  56. 6109.2012.02796.x.
  57. Lin C.F., Juang Y.Y., Wen J.K., Liu C.Y., Hung C.I. (2012). Correlation between sexual dysfunction, depression, anxiety, and somatic symptoms among patients with major depressive disorder. Chang Gung medical journal, 35(4): 323.31.
  58. Lorenz T.A., Meston C.M. (2012). Acute exercise improves physical sexual arousal in women taking antidepressants. Annals of behavioral medicine: a publication of the Society of Behavioral Medicine, 43(3): 352-61. DOI: 10.1007/s12160-001-9338-1
  59. Margolese H.C., Assalian P. (1996). Sexual side effects of antidepressants: a review.Journal of sex and marital therapy, 22: 209-217.
  60. Martin-Du P.R., Baumann P. (2008). Sexual dysfunctions induced by antadepressants and antipsychotics. Revue médicale suisse, 4(150): 758-62.
  61. Masiran R., Sidi H., Mohamed Z., Mohamed Saini S., Nik Jaafar N.R. (2013). Association between 5-HT2A polimorphism and selective serotonine re-uptake inhibitor (SSRI)-induced sexual desire disorder (SDD) among Malaysian women. Asia-Pacific psychiatry: official journal of the Pacific Rim College of Psychiatrists, 5 Suppl 1:41-9. DOI: 10.1111/appy.12043
  62. Masiran R., Sidi H., Mohamed Z., Mohd Nazree N.E., Nik Jaafar N.R., Midin M., Das S., Mohamed Saini S. (2014). Female sexual dysfunction in patients with Major Depressive Disorder (MDD) treated with Selective Serotonine Reuptake Inhibitor (SSRI) and its association with Serotonine 2A-1438 G/A Single Nucleotide
  63. Polimorphism. The Journal of Sexual Medicine, Feb 18. DOI: 10.1111/jsm.12452
  64. Millan M.J. (2005). Serotonine 5-HT2C receptors as a target for the treatment of depressive and anxious state: focus on novel therapeutic strategies. Thérapie, 60(5): 441-60.
  65. Modabbemia A., Sohrabi H., Nasehi A.A., Raisi F., Saroukhani S., Jamshidi A., Tabrizi M., Ashafi M., Akhondzadeh S. (2012). Effect of saffron on fluoxetineinduced sexual impairment in men: randomized double-blind placebo controlled trial. Psychopharmacology, 223(4): 381-8.
  66. Modell J.G., Katholi C.R., Modell J.D., De Palma R.L. (1997). Comparative se side effects of bupropion, fluoxetine, paroxetine and sertraline. Clinical Pharmacology and Therapeutics, 61: 476-487.
  67. Montejo A., Liorca G., Izquierdo J., Ledesma A., Bousoño M., Calcedo A., Carrasco J.L., Daniel E., de Dios A., de la Gàndara J., Derecho J., Franco M., Gòmez M.J., Macìas J.A., Martin T., Pèrez V., Sànchez J.M., Sànchez S., Vicens E. (1996). Sexual dysfunction secondary to SSRIs a comparative analysis in 308 patients. Actas luso-españolas de Neurología, Psiquiatría y Ciencias Afines, 24: 311-321.
  68. Montejo A., Liorca G., Izquierdo J., Rico-Villademoros F. (2001). Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. The Journal of Clinical Psychiatry, 62(3): 10-21.
  69. Montejo A., Majadas S., Rizvi S.J., Kennedy S.H. (2011). The effect of agomelatine on sexual function in depressed patients and healthy volunteers. Human Psychopharmacology, 26(8): 537-42. DOI: 10.1002/hup.1243
  70. Montejo A.L., Perahia D.G., Spann M.E., Wang F., Walker D.J., Yang C.R., Detke M.J. (2011). Sexual function during long-term duloxetine treatment in patients with recurrent major depressive disorder. The Journal of Sexual Medicine, 8(3): 773-82. DOI: 10.1111/j.1743-6109.2010.02113.x
  71. Moreira R. (2011). The efficacy and tolerability of bupropion in the treatment of major depressive disorder. Clinical Drug Investigation, 1:5-17. DOI: 10.2165/1159616-S0-0000000000-00000
  72. Musetti L., Pallanti S. (2003). Disturbi dell'umore. Depressione. In: Marazziti D., ed., Psicofarmacoterapia clinica. Roma: Giovanni Fioriti Editore, cap. 2, pp. 15-28.
  73. Nelson J.C., Portera L., Leon A.C. (2005). Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine. The Journal of Clinical Psychiatry, 66(11): 1409-14.
  74. Nutt D.J. (2002). Tolerability and safety aspects of mirtazapine. Human Psychopharmacology, 17(1): S37-41.
  75. Osvàth P., Fekete S., Vörös V., Almàsi J. (2005). Changes in sexual function in mirtazapine treatment. Primary data of a national, multicenter, prospective observational study in depressed patients. Neuropsychopharmacologia Hungarica: a Magyar Pszichofarmakológiai Egyesület lapja = official journal of the Hungarian Association of Psychopharmacology. 7(4): 177-86.
  76. Osvàth P., Fekete S., Vörös V., Almàsi J. (2007). Mirtazapine treatment and sexual functions: Results of a Hungarian, multicentre, prospective study in depressed out-patients. International Journal of Psychiatry in Clinical Practice, 11(3): 242-5. DOI: 10.1080/13651500701241147
  77. Patel K., Hellstrom W.J. (2009). Central regulation of ejaculation and therapeutic role of serotoninergic agents in premature ejaculation. Current Opinion in Investigational Drugs, 10(7): 681-90.
  78. Perlis R., Laje G., Smoller J., Fava M., Rush A., McMahon F. (2009). Genetic and clinical predictors of sexual dysfunction in citalopram-trated depressed patients. Neuropsychopharmacology, 34: 1819-1828 DOI: 10.1038/npp.2009.4
  79. Epub 2009 Mar 18. Reichenpfader U., Gartlehener G., Morgan L.C., Greenblatt A., Nussbaumer B., Hansen R.A., Van Noord M., Lux L., Gaynes B.N. (2014). Sexual dysfunction associated with second-generation antidepressants in patients with major depressive disorder: results from a sysstematic review with network metaanalysis. Drug Safety: an International Journal of Medical Toxicology and
  80. Drug Experience, 37(1): 19-31. DOI: 10.1007/s40264-013-0129-4
  81. Safa M., Sadr S., Talischi F., Boroujerdi F.G. (2013). Study of effects of serotonin reuptake inhibitors on stages of sexual function in Iranian patients with major depressive disorder. Therapeutic Advances in Psychopharmacology, 3(6): 306-313. DOI: 10.1177/2045125313488906
  82. Safarinejad M.R. (2010). The effects of the adjuntive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inibitor: a double-blind placebo-controlled and randomized study. BJU international, 106(6): 840-7. DOI: 10.1111/j.1464-410X2009.09154.x
  83. Safarinejad M.R., Hosseini S.Y., Asgari M.A., Dadkhah F., Taghva A. (2010). A randomized, double-blind, placebo-controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women. BJU international, 106: 832-839 DOI: 10.1111/j.1464-410X.2010.09208.
  84. Saiz-Ruiz J., Montes J.M., Ibanez A., Diaz M., Vicente F., Pelegrin C., Viñas R., Arias F., Carrasco J.L., Ferrando L. (2005). Assessment of sexual functioning in depressed patients treated with mirtazapine: a naturalistic 6-month study. Human Psychopharmacology, 20(6): 435-440.
  85. Shen W.W., Sata L.S. (1983). Inhibited female orgasm resulting from psychotropic drugs. A clinical review. The Journal of Reproductive Medicine, 28(7): 497-9.
  86. Shen W.W., Mallya A.R. (1983). MAOI-induced inhibited female orgasm. The American Journal of Psychiatry,140(9): 1275.
  87. Schweitzer I., Maguire K., Ng C. (2009). Sexual side-effects of contemporary antidepressants: review. The Australian and New Zealand Journal of Psychiatry, 43(9): 795-808. DOI: 10.1080/00048670903107575
  88. Segraves R.T., Croft H., Kavoussi R., Ascher J.A., Batey S.R., Foster V.J., Bolden-Watson C., Metz A. (2001). Bupropion sustained release (SR) for the treatment of the hypoactive sexual desire disorder (HSDD) in non depressed women. Journal of Sex and Marital Therapy, 27: 303-316.
  89. Segraves R.T., Balon R. (2013). Antidepressant-induced sexual dysfunction in men. Pharmacology, Biochemistry and Behavior. DOI.org/10.1016/j.pbb.2013.11.003.
  90. Serretti A., Chiesa A. (2009). Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. Journal of Clinical Psychopharmacology, 29(3): 259-266. DOI: 10.1097/JCP.0b013e3181a5233f
  91. Serretti A., Chiesa A. (2010). Antidepressivi e disfunzione sessuale: epidemiologia, meccanismi e strategie di trattamento. Giornale Italiano di Psicopatologia, 16: 104-113. Serretti A., Chiesa A. (2011). Sexual side effects of pharmacological treatment of psychiatric diseases. Clinical Pharmacology and Therapeutics, 89: 142-147.
  92. Shalev H., Ben-Zion I., Shiber A. (2009). A case of mirtazapine-induced spontaneous orgasms in a female patient. Journal of Psychopharmacology, 23(1): 109-10. DOI: 10.1177/0269881107083847
  93. Sidi H., Asmidar D., Hod R., Guan N.C. (2012). Female sexual dysfunction in patients treated with antidepressant-comparison between escitalopram and fluoxetine. The Journal of Sexual Medicine, 9(5): 1392-9. DOI: 10.1111/j.1743-6109.2011.02256.x
  94. Stahl S.M., Lee-Zimmerman C., Cartwright S., Morrisette D.A. (2013). Serotoninergic drugs for depression and beyond. Current Drug Targets, 14(5): 578-85.
  95. Strohmaier J., Wüst S., Uher R., Henigsberg N., Mors O., Hauser J., Souery D., Zobel A., Demovsek M.Z., Streit F., Schmäl C., Kozel D., Placentino A., Farmer A., Mc Guffin P., Aichison K.L., Rietschel M. (2011). Sexual dysfunction during treatment with serotonergic and noradrenergic antidepressants: clinical description and the role of the 5-HTTLPR. The World Journal of Biological Psychiatry: the official journal of the World Federation of Societies of Biological Psychiatry, 12(7):528-38. DOI: 10.3109/15622975.2011.559270
  96. Takurta R.G., Singh O.P., Bhattacharya A., Mallick A.K., Ray P., Sen S., Das R. (2012). Nature of sexual dysfunctions in major depressive disorder and its impact on quality of life. Indian Journal of Psychological Medicine, 34(4): 365-70. DOI: 10.4103/0253-7176.108222
  97. Targo􀄔ski A., Prajsner A. (2012). Treatment of premature ejaculation. Wiadomo􀄞ci Lekarskie, 65(1): 44-7.
  98. Taylor M.J., Rudkin I., Bullemor-Day P., Lubin J., Chukwujekwu C., Hawton K. (2013). Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database of Systematic Reviews, Issue 5. Art. No.: CD003382. DOI: 10.1002/14651858.CD003382.pub3
  99. Uphouse L. (2013). Pharmacology of serotonine and female sexual behavior. Pharmacology, Biochemistry and Behavior. DOI: 10.1016/j.pbb.2013.11.008
  100. Whiskey E., Taylor D. (2013). A review of the adverse effects and safety of noradrenergic antidepressants. Journal of Psychopharmacology, 27(8): 732-9. DOI: 10.1177/0269881113492027
  101. Zemishlani Z., Weizman A. (2008). The impact of mental illness on sexual dysfunction. Advances in psychosomatic medicine, 29: 89-106 DOI: 10.1159/00012662
  102. Zourkovà A., Hadasovà E. (2002). Relationship between CYP2D6 metabolic status and sexual dysfunction in paroxetine treatment. Journal of Sex and Marital Therapy, 28: 451-461.
  103. Zourkovà A., Novotnà J. (2006). Gender differences in efficacy and sexual function in long-term trazodone treatment (preliminary results). International Journal of Psychiatry in Clinical Practice, 10(3): 154-9. DOI: 10.1080/13651500500443316
  104. Zourkovà A., Ceskavà E., Hadasovà E., Ravcukovà B. (2007). Links among paroxetine-induced sexual dysfunctions, gender, and CYP2D6 activity. Journal of Sex and Marital Therapy, 33: 343-355.

Luigi Lombardo, Roberta Rossi, Disfunzioni sessuali correlate al trattamento del disturbo depressivo maggiore con farmaci antidepressivi in "RIVISTA DI SESSUOLOGIA CLINICA" 2/2014, pp 57-80, DOI: 10.3280/RSC2014-002003